CA1297409C - Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics - Google Patents

Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics

Info

Publication number
CA1297409C
CA1297409C CA000533564A CA533564A CA1297409C CA 1297409 C CA1297409 C CA 1297409C CA 000533564 A CA000533564 A CA 000533564A CA 533564 A CA533564 A CA 533564A CA 1297409 C CA1297409 C CA 1297409C
Authority
CA
Canada
Prior art keywords
base material
therapeutic agent
dosage form
unit dosage
recited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000533564A
Other languages
English (en)
French (fr)
Inventor
Hans Lowey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1297409C publication Critical patent/CA1297409C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000533564A 1986-04-04 1987-04-01 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics Expired - Lifetime CA1297409C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US848,702 1986-04-04
US06/848,702 US4775535A (en) 1986-04-04 1986-04-04 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics

Publications (1)

Publication Number Publication Date
CA1297409C true CA1297409C (en) 1992-03-17

Family

ID=25304046

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000533564A Expired - Lifetime CA1297409C (en) 1986-04-04 1987-04-01 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics

Country Status (14)

Country Link
US (1) US4775535A (es)
EP (1) EP0240351B1 (es)
JP (1) JPH0751519B2 (es)
AT (1) ATE77740T1 (es)
AU (1) AU591258B2 (es)
CA (1) CA1297409C (es)
DE (1) DE3780056T2 (es)
ES (1) ES2005549A6 (es)
GR (1) GR3005851T3 (es)
IL (1) IL82092A (es)
MX (1) MX5864A (es)
PL (1) PL264984A1 (es)
YU (1) YU46312B (es)
ZA (1) ZA871818B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5225201A (en) * 1991-08-23 1993-07-06 Minnesota Mining And Manufacturing Company Salsalate tablet
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
CA2354057C (en) 1998-12-11 2009-02-10 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
CN107569690A (zh) * 2012-01-04 2018-01-12 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2980589A (en) * 1958-09-12 1961-04-18 American Cyanamid Co Process for producing anhydrous granulation of a medicinally active waterlabile powder
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3957525A (en) * 1971-04-24 1976-05-18 Dunlop Limited Road surfacing materials
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
CA945899A (en) * 1971-09-16 1974-04-23 Hans Lowey Long-acting oral carrier
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
GB1430684A (en) * 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
AU591258B2 (en) 1989-11-30
EP0240351A3 (en) 1988-03-02
MX5864A (es) 1994-01-31
EP0240351A2 (en) 1987-10-07
DE3780056T2 (de) 1992-12-24
IL82092A (en) 1990-09-17
IL82092A0 (en) 1987-10-30
YU56987A (en) 1988-08-31
US4775535A (en) 1988-10-04
ATE77740T1 (de) 1992-07-15
EP0240351B1 (en) 1992-07-01
JPH0751519B2 (ja) 1995-06-05
DE3780056D1 (de) 1992-08-06
JPS62294626A (ja) 1987-12-22
ZA871818B (en) 1987-09-02
GR3005851T3 (es) 1993-06-07
YU46312B (sh) 1993-05-28
PL264984A1 (en) 1989-03-20
AU7099887A (en) 1987-10-08
ES2005549A6 (es) 1989-03-16

Similar Documents

Publication Publication Date Title
CA1297409C (en) Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4855143A (en) Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
CA2592173C (en) Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
CA1273873A (en) Slow release solid preparation
EP0309157B1 (en) Sustained release etodolac
EP0305051B1 (en) Orally sustained-release acetaminophen formulation and process to obtain it
US4851226A (en) Chewable medicament tablet containing means for taste masking
EP0656775B1 (en) Sustained release tablets containing bupropion
EP0459695B1 (en) Taste masking and sustained release coatings for pharmaceuticals
US5047246A (en) Direct compression cyclophosphamide tablet
EP0879049A1 (en) Process to prepare soluble delivery systems using volatile salts
SU1577684A3 (ru) Способ получени таблеток
KR100322340B1 (ko) 경구 콜레스테롤 저하제
US4837032A (en) Theophylline sustained release tablet
US20110177168A1 (en) Composition
US4631284A (en) Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
HU219462B (hu) Asztemizolt és pszeudoefedrint tartalmazó, nyújtott hatású, filmbevonatos tabletták
US4925675A (en) Erythromycin microencapsulated granules
AU753482B2 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
JP2599189B2 (ja) 味覚遮蔽剤を含有している咀嚼可能な薬物錠剤
EP0181650B1 (en) Compression-coated dispersible tablets
IL106743A (en) Tablets with enhanced bioavailability of claudonic acid
EP0266707A2 (en) Sustained release labetalol tablet
JPH04243819A (ja) 徐放性製剤
AU2019254487B2 (en) Sustained release pyridostigmine compositions

Legal Events

Date Code Title Description
MKLA Lapsed